Literature DB >> 17449017

High content screen microscopy analysis of A beta 1-42-induced neurite outgrowth reduction in rat primary cortical neurons: neuroprotective effects of alpha 7 neuronal nicotinic acetylcholine receptor ligands.

Min Hu1, Mark E Schurdak, Pamela S Puttfarcken, Rachid El Kouhen, Murali Gopalakrishnan, Jinhe Li.   

Abstract

beta-Amyloid peptide 1-42 (A beta(1-42)) is generated from amyloid precursor protein (APP) and associated with neurodegeneration in Alzheimer's disease (AD). A beta(1-42) has been shown to be cytotoxic when incubated with cultured neurons. However, APP transgenic mice over-expressing A beta(1-42) do not show substantial loss of neurons, despite deficits in learning and memory. It is thus emerging that A beta(1-42)-induced memory deficits may involve subtler neuronal alternations leading to synaptic deficits, prior to frank neurodegeneration in AD brains. In this study, high content screen (HCS) microscopy, an advanced high-throughput cellular image processing and analysis technique, was utilized in establishing an in vitro model of A beta(1-42)-induced neurotoxicity utilizing rat neonatal primary cortical cells. Neurite outgrowth was found to be significantly reduced by A beta(1-42) (300 nM to 30 microM), but not by the scrambled control peptide control, in a time- and concentration-dependent manner. In contrast, no reduction in the total number of neurons was observed. The A beta(1-42)-induced reduction of neurite outgrowth was attenuated by the NMDA receptor antagonist memantine and the alpha 7 nicotinic acetylcholine receptor (nAChR) selective agonist PNU-282987. Interestingly, the alpha 7 nAChR antagonist methyllycaconitine also significantly prevented reduction in A beta(1-42)-induced neurite outgrowth. The observed neuroprotective effects could arise either from interference of A beta(1-42) interactions with alpha 7 nAChRs or by modification of receptor-mediated signaling pathways. Our studies demonstrate that reduction of neurite outgrowth may serve as a model representing A beta(1-42)-mediated neuritic and synaptic toxicity, which, in combination of HCS, provides a high-throughput cell-based assay that can be used to evaluate compounds with neuroprotective properties in neurons.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449017     DOI: 10.1016/j.brainres.2007.03.051

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  23 in total

Review 1.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

Review 3.  Cancer 'survivor-care': I. the α7 nAChR as potential target for chemotherapy-related cognitive impairment.

Authors:  R B Raffa
Journal:  J Clin Pharm Ther       Date:  2010-08-24       Impact factor: 2.512

4.  The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide.

Authors:  C Kurz; I Ungerer; U Lipka; S Kirr; T Schütt; A Eckert; K Leuner; W E Müller
Journal:  Br J Pharmacol       Date:  2010-03-09       Impact factor: 8.739

Review 5.  Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.

Authors:  Md Sahab Uddin; Abdullah Al Mamun; Md Tanvir Kabir; Ghulam Md Ashraf; May N Bin-Jumah; Mohamed M Abdel-Daim
Journal:  Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.590

6.  Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Authors:  Frank G Boess; Jean de Vry; Christina Erb; Timo Flessner; Martin Hendrix; Joachim Luithle; Christoph Methfessel; Katrin Schnizler; F Josef van der Staay; Marja van Kampen; Welf-Burkhard Wiese; Gerhard König
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

7.  Positive allosteric modulation of alpha7 neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat primary cortical neurons.

Authors:  Min Hu; Murali Gopalakrishnan; Jinhe Li
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

8.  Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam.

Authors:  Kristina Leuner; Christopher Kurz; Giorgio Guidetti; Jean-Marc Orgogozo; Walter E Müller
Journal:  Front Neurosci       Date:  2010-09-07       Impact factor: 4.677

9.  γ-Aminobutyric acid type A receptor inhibition triggers a nicotinic neuroprotective mechanism.

Authors:  P A Ferchmin; Dinely Pérez; William Castro Alvarez; Mario A Penzo; Héctor M Maldonado; Vesna A Eterovic
Journal:  J Neurosci Res       Date:  2012-12-26       Impact factor: 4.164

10.  Pharmacology of alpha7 nicotinic acetylcholine receptor mediated extracellular signal-regulated kinase signalling in PC12 cells.

Authors:  R El Kouhen; M Hu; D J Anderson; J Li; M Gopalakrishnan
Journal:  Br J Pharmacol       Date:  2009-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.